
Opinion|Videos|February 16, 2024
BRIDGET: Preventing Secondary Brain Metastases in Advanced HER2+ Breast Cancer
Carey Anders, MD, offers insights into the BRIDGET trial, a study investigating the role of tucatinib in the prevention of secondary brain metastases in patients with advanced HER2-positive breast cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
3
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
4
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
5



























































